Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 years and older.The lower age limit may be higher if legally required in the participating country~* Women of childbearing potential can only be included in the study if a pregnancy test is negative and if they agree to use adequate contraception when sexually active.~* Subjects with type 2 diabetes mellitus fulfilling at least 1 of the following criteria~  * are on oral antidiabetics and / or insulin,~ * have a documented fasting glucose \>/= 7.0 mmol/L in the medical history,~ * have a 2 hour plasma glucose \>/=11.1 mmol/L during an oral glucose tolerance test in the medical history, or~ * have a glycated hemoglobin (HbA1c) \>/=6.5% \[National Glycohemoglobin Standardization Program (NGSP) / Diabetes Control and Complications Trial (DCCT)\] in the medical history or at the run-in visit~* Subjects with a clinical diagnosis of diabetic nephropathy (DN) based on at least 1 of the following criteria:~  * Persistent very high albuminuria defined as urinary albumin-to-creatine ratio (UACR) of \>/=300 mg/g ( \>/= 34 mg/mmol) in 2 out of 3 first morning void samples and estimated glomerular filtration rate (eGFR) \>/=30 mL/min/1.73 m² but \< 90 mL/min/1.73m² (Chronic Kidney Disease Epidemiology Collaboration, CKD EPI) (mL = milliliter; min = minute; m2 = square meter; g = gram; mmol = millimole) or~ * Persistent high albuminuria defined as UACR of \>/=30 mg/g but \<300 mg/g in (\>/=3.4mg/mmol but \<34 mg/mmol) in 2 out of 3 first morning void samples and eGFR \>/=30 mL/min/1.73 m² but \< 90 mL/min/1.73m²~* Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) for at least 3 months without any adjustments to this therapy for at least 4 weeks prior to the screening visit~* Serum potassium \</= 4.8 mmol/L at both the run-in visit and the screening visit~Exclusion Criteria:~* Non-diabetic renal disease~* Glycated hemoglobin (HbA1c) \>12% at the run-in visit or the screening visit~* UACR \>3000 mg/g (339mg/mmol) in any of the urinary first morning void samples at the run-in visit or screening visit~* Hypertension with mean sitting systolic blood pressure (SBP) \>/=180 mmHg or mean sitting diastolic blood pressure (DBP) \>/=110 mmHg at the run-in visit or mean supine SBP \>/=160 mmHg or mean sitting DBP \>/=100 mmHg at the screening visit~* Subjects with a clinical diagnosis of heart failure with reduced ejection fraction (HFrEF) and persistent symptoms (New York Heart Association class II-IV) at the run-in visit~* Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or potassium-sparing diuretic~* Dialysis for acute renal failure within the previous 6 months prior to the run-in visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Finerenone (BAY94-8862) (1.25 mg) (Type: EXPERIMENTAL): 1.25 mg dose oral once daily for 90 days
- Finerenone (BAY94-8862)(2.5 mg) (Type: EXPERIMENTAL): 2.5 mg dose oral once daily for 90 days
- Finerenone (BAY94-8862)(5 mg) (Type: EXPERIMENTAL): 5 mg dose oral once daily for 90 days
- Finerenone (BAY94-8862)(7.5 mg) (Type: EXPERIMENTAL): 7.5 mg dose oral once daily for 90 days
- Finerenone (BAY94-8862) (10 mg) (Type: EXPERIMENTAL): 10 mg dose oral once daily for 90 days
- Finerenone (BAY94-8862) (15 mg) (Type: EXPERIMENTAL): 15 mg dose oral once daily for 90 days
- Finerenone (BAY94-8862)(20 mg) (Type: EXPERIMENTAL): 20 mg dose oral once daily for 90 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral dose once daily for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).